[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"omega-3\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:omega-3":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100643710","effects-of-dietary-supplementation-with-omega3-fatty-acids-fish-oil-and-progressive-resistance-training-on-skeletal-muscle-status-in-gynaecological-gastrointestinal-and-urological-cancer-patients-100643710",false,"NCT07643558","Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients","SUPPORT-Study = Effects of a Dietary SUPPlementation With Omega3-fatty Acids\u002F Fish Oil and Progressive Resistence Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal, and Urological Cancer Patients","SUPPORT","Inclusion Criteria:\n\n* Patients with malignant tumors undergoing curative or palliative treatment, including breast, ovarian, esophageal, pancreatic, gastric, colon, rectal, and prostate cancer, across all UICC stages\n* Women and men aged 18 years or older\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Bone metastases or skeletal involvement associated with a high risk of fracture\n* Pregnant or breastfeeding women\n* Patients with psychiatric disorders that raise concerns regarding decision-making capacity or ability to provide informed consent\n* Participation in other exercise and\u002For nutritional intervention studies within the previous 3 months\n* Current use of fish oil supplements\n* Severe cardiovascular disease, NYHA class IV","ALL","18 Years",{"count":20,"type":21},288,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life.\n\nIn addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass.\n\nThe aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.",[27,28,29,30,31,32],"Cancer Cachexia","Omega 3","Resistance Training","Cancer","Muscle Wasting","Systemic Inflammation",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Resistance training","Progressive resistance exercise","Exercise therapy","Supportive cancer care","Nutritional intervention","Protein-rich nutrition","Nutritional supplementation","Omega-3 fatty acids","Eicosapentaenoic acid (EPA)","Docosahexaenoic acid (DHA)","Fish oil supplementation","Physical performance","Quality of life","Fatigue","Appetite","Patient-reported outcomes","Randomized placebo-controlled trial","Cachexia risk","RECRUITING","2026-06-08",{"date":55,"type":56},"2026-06-11","ACTUAL",{"date":58,"type":56},"2026-01-01",{"date":60,"type":21},"2029-10",{"name":62,"class":63},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":64},"100591039","phase-4-observing-metabolism-of-epa-with-consideration-of-genetics-and-sex-100591039","NCT06975241","Observing Metabolism of EPA With Consideration of Genetics And Sex","Determining Contribution of Sex and Genetics to DHA Synthesis Rates Over 12 Weeks of EPA Supplementation in Healthy Individuals","OMEGA","Inclusion Criteria:\n\n* BMI between 18.5- 30 kg\u002Fm2\n* healthy\n\nExclusion Criteria:\n\n* Consumption of fish\u002Fseafood or EPA\u002FDHA-enriched foods currently or within the previous 6 months\n* Consumption of any supplements containing ALA\u002FEPA\u002FDHA currently or within the previous 6 months\n* Allergies to any component of the study supplement (fish, gelatin etc.)\n* BMI \\\u003C18.5 kg\u002Fm² or \\>30 kg\u002Fm²\n* Women who are pregnant, breastfeeding or planning on becoming pregnant\n* Diagnosis with chronic or communicable diseases\n* Prescription of chronic pharmacological medications (except for oral contraceptives)\n* High blood pressure (systolic or diastolic blood pressure above 130 or 80mmHg, respectively)\n* Hypertriglyceridemia (serum \\> or = 1.69 mmol\u002Fl)\n* Hypercholesterolemia (serum LDL-C \\> or =5 mmol\u002Fl)\n* Anticipated changes in lifestyle within the next 4 months\n* Smoking\n* Heavy alcohol use (\\>3 drinks\u002Fday)\n* Major surgery in the last six months",true,"35 Years",{"count":76,"type":21},64,[78],"PHASE4","The goal of this clinical study is to learn how fast EPA is converted to other molecules, including DHA, with consideration of biological sex and genetics in healthy humans.\n\nThe main questions it aims to answer are:\n\n* How fast is EPA converted to DHA in blood, and is the conversion rate affected by sex and a specific genotype we previously identified?\n* How do sex and the specific genotypes affect blood DHA levels and other products of DHA in response to dietary EPA?\n* How fast does dietary EPA replace blood EPA and other omega-3 fatty acids, and is the rate affected by sex and genotype?\n\nParticipants will be asked to take EPA supplements for 12 weeks and provide a series of venous blood samples over the study duration.",[81,28,82],"Healthy","Metabolism, Lipids",[84,85,86,87,88,89,90],"eicosapentaenoic acid","omega-3 polyunsaturated fatty acids","lipid metabolism","healthy adults","docosahexaenoic acid","single nucleotide polymorphism","elongation of very long-chain 2","2026-02-25",{"date":93,"type":56},"2026-02-27",{"date":95,"type":56},"2025-07-29",{"date":97,"type":21},"2026-09",{"name":99,"class":63},"University of Toronto"]